Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program PR Newswire WALTHAM, Mass., Dec. 10, 2024 -- SIGNAL-AA demonstrated encouraging...
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Nov. 7, 2024 -- Bempikibart Phase 2 topline results in atopic dermatitis (AD) and...
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference PR Newswire WALTHAM, Mass., Nov. 5, 2024 WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0007 | 0.0217391304348 | 3.22 | 3.39 | 2.99 | 217142 | 3.18836811 | CS |
4 | -0.0393 | -1.20552147239 | 3.26 | 4.1499 | 2.99 | 385011 | 3.44787609 | CS |
12 | -44.5793 | -93.2621338912 | 47.8 | 53.17 | 2.99 | 374885 | 9.29676706 | CS |
26 | -23.4393 | -87.9193548387 | 26.66 | 53.79 | 2.99 | 223468 | 17.9256334 | CS |
52 | -13.0193 | -80.1681034483 | 16.24 | 53.79 | 2.99 | 163844 | 18.58414635 | CS |
156 | -13.0193 | -80.1681034483 | 16.24 | 53.79 | 2.99 | 163844 | 18.58414635 | CS |
260 | -13.0193 | -80.1681034483 | 16.24 | 53.79 | 2.99 | 163844 | 18.58414635 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.